HK1082737A1 - Triheterocyclic compounds, compositions, and methods for treating cancer - Google Patents

Triheterocyclic compounds, compositions, and methods for treating cancer

Info

Publication number
HK1082737A1
HK1082737A1 HK06105160.7A HK06105160A HK1082737A1 HK 1082737 A1 HK1082737 A1 HK 1082737A1 HK 06105160 A HK06105160 A HK 06105160A HK 1082737 A1 HK1082737 A1 HK 1082737A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
treating cancer
triheterocyclic
compounds
Prior art date
Application number
HK06105160.7A
Other languages
English (en)
Inventor
Giorgio Attardo
Kenza Dairi
Jean-Francois Lavallee
Elise Rioux
Sasmita Tripathy
Xavier Billot
Terrence W Doyle
Original Assignee
Gemin X Pharmaceuticals Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemin X Pharmaceuticals Canada Inc filed Critical Gemin X Pharmaceuticals Canada Inc
Publication of HK1082737A1 publication Critical patent/HK1082737A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK06105160.7A 2003-05-30 2006-05-02 Triheterocyclic compounds, compositions, and methods for treating cancer HK1082737A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47474103P 2003-05-30 2003-05-30
PCT/CA2004/000793 WO2004106328A1 (fr) 2003-05-30 2004-05-28 Composes triheterocycliques, compositions et procedes de traitement du cancer ou de maladies virales

Publications (1)

Publication Number Publication Date
HK1082737A1 true HK1082737A1 (en) 2006-06-16

Family

ID=33490730

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06105160.7A HK1082737A1 (en) 2003-05-30 2006-05-02 Triheterocyclic compounds, compositions, and methods for treating cancer

Country Status (24)

Country Link
US (4) US7425553B2 (fr)
EP (1) EP1644363B1 (fr)
JP (1) JP4980715B2 (fr)
KR (1) KR101168441B1 (fr)
CN (1) CN1832939B (fr)
AT (1) ATE546456T1 (fr)
AU (1) AU2004242928B2 (fr)
BR (1) BRPI0410870A (fr)
CA (1) CA2527583C (fr)
CY (1) CY1113038T1 (fr)
DK (1) DK1644363T3 (fr)
ES (1) ES2382377T3 (fr)
HK (1) HK1082737A1 (fr)
HR (1) HRP20120379T1 (fr)
IL (1) IL172189A (fr)
MX (1) MXPA05012799A (fr)
NO (1) NO333006B1 (fr)
NZ (1) NZ543897A (fr)
PL (1) PL1644363T3 (fr)
PT (1) PT1644363E (fr)
RU (1) RU2360913C2 (fr)
SI (1) SI1644363T1 (fr)
WO (1) WO2004106328A1 (fr)
ZA (1) ZA200509718B (fr)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060035945A1 (en) * 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
EP1644363B1 (fr) * 2003-05-30 2012-02-22 Gemin X Pharmaceuticals Canada Inc. Composes triheterocycliques, compositions et procedes de traitement du cancer
WO2005112640A2 (fr) * 2004-05-13 2005-12-01 Viropharma Incorporated Composes, compositions et methodes de traitement et de prophylaxie des infections provoquees par le virus de l'hepatite c et des maladies associees
ES2454551T3 (es) * 2004-12-28 2014-04-10 Gemin X Pharmaceuticals Canada Inc. Compuestos dipirrólicos, composiciones, y métodos para el tratamiento del cáncer o enfermedades virales
WO2006089397A1 (fr) * 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Procédés pour traiter l’arthrite à l’aide de composés trihétérocycliques
US7994360B2 (en) * 2005-05-16 2011-08-09 Xtl Biopharmaceuticals Ltd. Benzofuran compounds
US20080051400A1 (en) * 2006-07-06 2008-02-28 Gemin X Biotechnologies Inc. Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound
WO2008136815A2 (fr) 2006-12-22 2008-11-13 Schering Corporation Dérivés indoliques annelés à cycle à 5 ou 6 éléments et leurs méthodes d'utilisation
KR20090106539A (ko) 2006-12-22 2009-10-09 쉐링 코포레이션 Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
MX2009006880A (es) 2006-12-22 2009-07-03 Schering Corp Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas.
WO2008121814A1 (fr) 2007-03-28 2008-10-09 Ats Medical, Inc. Procédé pour inhiber l'interaction des plaquettes avec les surfaces de biomatériaux
TW200924751A (en) 2007-08-29 2009-06-16 Schering Corp 2,3-substituted indole derivatives and methods of use thereof
JP5258889B2 (ja) 2007-08-29 2013-08-07 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス感染症の治療のための２，３−置換アザインドール誘導体
KR20100067652A (ko) 2007-08-29 2010-06-21 쉐링 코포레이션 치환된 인돌 유도체 및 이의 사용방법
CN101130539B (zh) * 2007-09-26 2012-05-30 浙江大学 吲哚取代咪唑啉-2-酮类衍生物及其制备方法和用途
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
CA2705586A1 (fr) 2007-11-16 2009-05-22 Schering Corporation Derives d'indole a substitution heterocyclique en position 3 et leurs procedes d'utilisation
CN102317285A (zh) 2007-11-16 2012-01-11 先灵公司 3-氨基磺酰基取代的吲哚衍生物及其使用方法
JP5580814B2 (ja) 2008-06-13 2014-08-27 メルク・シャープ・アンド・ドーム・コーポレーション ３環式インドール誘導体およびその使用方法
US9168236B2 (en) 2011-04-08 2015-10-27 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and pharmaceutical compositions for inhibiting influenza viruses replication
CN104039797B (zh) * 2011-10-12 2016-06-01 南京奥昭生物科技有限公司 作为细胞凋亡诱导剂的杂环分子
US20150313906A1 (en) * 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
CN103044311B (zh) * 2012-12-26 2015-04-22 山东大学 一种多取代吲哚类化合物及其制备方法和应用
WO2014160071A1 (fr) * 2013-03-14 2014-10-02 St. Jude Children's Research Hospital Procédés et compositions pour le traitement de cancers dépendants à la glutamine
WO2015131080A1 (fr) 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Inhibiteurs de tyk2 et leurs utilisations
US11331328B2 (en) 2014-05-05 2022-05-17 Bioventures, Llc Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents
WO2016014625A1 (fr) 2014-07-22 2016-01-28 Board Of Trustees Of The University Of Arkansas Compositions et procédés de déplétion sélective de cellules sénescentes
US11311512B2 (en) 2014-08-12 2022-04-26 Monash University Lymph directing prodrugs
US20160251376A1 (en) 2015-02-27 2016-09-01 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
US20180221393A1 (en) 2015-08-03 2018-08-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases
EP3344624B8 (fr) 2015-09-02 2023-11-29 Takeda Pharmaceutical Company Limited Inhibiteurs de tyk2 et leurs utilisations
CN108137482B (zh) 2015-09-08 2024-03-15 莫纳什大学 定向淋巴的前药
WO2017044720A1 (fr) 2015-09-11 2017-03-16 Navitor Pharmaceuticals, Inc. Analogues de la rapamycine et leurs utilisations
US20170087125A1 (en) * 2015-09-30 2017-03-30 Augusta University Research Institute, Inc. Flavonoid compositions for the treatment of cancer
SI3364958T1 (sl) 2015-10-23 2023-05-31 Navitor Pharmaceuticals, Inc. Modulatorji interakcije sestrina in gator2 ter njihova uporaba
EP3389664A4 (fr) 2015-12-14 2020-01-08 Raze Therapeutics Inc. Inhibiteurs de caféine de mthfd2 et leurs utilisations
US11014882B2 (en) * 2016-03-09 2021-05-25 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
DK3426243T3 (da) 2016-03-09 2021-07-19 Raze Therapeutics Inc 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf
CN109195593A (zh) 2016-03-15 2019-01-11 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
CA3017408A1 (fr) 2016-03-15 2017-09-21 Oryzon Genomics, S.A. Combinaisons d'inhibiteurs de lsd1 pour le traitement des malignites hematologiques
WO2017177230A1 (fr) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Méthodes de traitement du cancer
US10870640B2 (en) 2016-04-08 2020-12-22 Institute For Cancer Research Prodigiosin analogs and methods of use
WO2017177216A1 (fr) * 2016-04-08 2017-10-12 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Analogues de la prodigiosine
US10807977B2 (en) 2016-04-21 2020-10-20 Bioventures, Llc Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof
JP7084624B2 (ja) 2016-06-21 2022-06-15 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
EP3471727B1 (fr) 2016-06-21 2020-12-09 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
AU2017342464B2 (en) 2016-10-14 2021-09-16 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
EP3528816A4 (fr) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. Inhibiteurs de tyk2 et leurs utilisations
EP3538091A4 (fr) 2016-11-08 2020-06-10 Navitor Pharmaceuticals, Inc. Inhibiteurs de la phényl amino pipéridine mtorc et leurs utilisations
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
WO2018106636A1 (fr) 2016-12-05 2018-06-14 Raze Therapeutics, Inc. Inhibiteurs de shmt et leurs utilisations
EP3565638B8 (fr) 2017-01-06 2024-04-10 BicycleRD Limited Conjugué bicyclique pour traiter le cancer
TWI783978B (zh) 2017-03-08 2022-11-21 美商林伯士拉克許米公司 Tyk2抑制劑、其用途及生產方法
EP3375784A1 (fr) 2017-03-14 2018-09-19 Artax Biopharma Inc. Dérivés d'aza-dihydro-acridone
EP3375778A1 (fr) 2017-03-14 2018-09-19 Artax Biopharma Inc. Dérivés d'aryl-pipéridine
US11339144B2 (en) 2017-04-10 2022-05-24 Navitor Pharmaceuticals, Inc. Heteroaryl Rheb inhibitors and uses thereof
TWI776886B (zh) 2017-04-26 2022-09-11 美商奈維特製藥公司 Sestrin-gator2交互作用之調節劑及其用途
JP7216705B2 (ja) 2017-07-28 2023-02-02 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用方法
CA3077739A1 (fr) 2017-08-29 2019-03-07 Puretech Lyt, Inc. Promedicaments lipidiques orientant vers le systeme lymphatique
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
IL295603B2 (en) 2017-09-22 2024-03-01 Kymera Therapeutics Inc Protein compounds and their uses
WO2019126378A1 (fr) 2017-12-19 2019-06-27 Ariya Therapeutics, Inc. Promédicaments lipidiques d'acide mycophénolique et leurs utilisations
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
IL275649B2 (en) 2017-12-26 2023-12-01 Kymera Therapeutics Inc IRAK joints and used in them
EP3737675A4 (fr) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Ligands crbn et leurs utilisations
WO2019140380A1 (fr) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Agents de dégradation de protéines et utilisations associées
JP7385284B2 (ja) 2018-01-22 2023-11-22 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニー 癌処置のためのｂｃｌ－２タンパク質分解剤
CN111867581B (zh) 2018-01-29 2023-12-26 默克专利股份有限公司 Gcn2抑制剂及其用途
KR20200116481A (ko) 2018-01-29 2020-10-12 메르크 파텐트 게엠베하 Gcn2 억제제 및 이의 용도
EA202091742A1 (ru) 2018-02-27 2021-02-19 Артакс Биофарма Инк. ПРОИЗВОДНЫЕ ХРОМЕНА В КАЧЕСТВЕ ИНГИБИТОРОВ ВЗАИМОДЕЙСТВИЯ TCR-Nck
JP7479293B2 (ja) 2018-04-24 2024-05-08 バーテックス ファーマシューティカルズ インコーポレイテッド プテリジノン化合物およびその使用
TWI813673B (zh) 2018-04-24 2023-09-01 德商馬克專利公司 抗增生化合物及其用途
FI3813946T3 (fi) 2018-06-15 2024-06-25 Janssen Pharmaceutica Nv Rapamysiinianalogeja ja niiden käyttötapoja
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
EP3817748A4 (fr) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. Ligands crbn tricycliques et leurs utilisations
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
JP2022500499A (ja) 2018-09-07 2022-01-04 ピク セラピューティクス， インコーポレイテッド Ｅｉｆ４ｅ阻害剤およびその使用
AU2019360941A1 (en) 2018-10-15 2021-04-29 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
CA3117336A1 (fr) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphies d'acide (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoique pour la modulation de mtorc1
EP3886843A4 (fr) 2018-11-30 2022-08-31 Nimbus Lakshmi, Inc. Inhibiteurs de tyk2 et leurs utilisations
CN113423427A (zh) 2018-11-30 2021-09-21 凯麦拉医疗公司 Irak降解剂和其用途
EP3670659A1 (fr) 2018-12-20 2020-06-24 Abivax Biomarqueurs et leurs utilisations dans le traitement d'infections virales, d'inflammations ou du cancer
CN113348021A (zh) 2019-01-23 2021-09-03 林伯士拉克许米公司 Tyk2抑制剂和其用途
SG11202110828UA (en) 2019-04-02 2021-10-28 Bicycletx Ltd Bicycle toxin conjugates and uses thereof
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
WO2020243423A1 (fr) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
AU2020345962A1 (en) 2019-09-11 2022-03-31 Vincere Biosciences, Inc. USP30 inhibitors and uses thereof
JP2022547719A (ja) 2019-09-13 2022-11-15 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニストおよびその使用
EP4051259A4 (fr) 2019-11-01 2023-11-22 Navitor Pharmaceuticals, Inc. Méthodes de traitement à l'aide d'un modulateur de mtorc1
US11819476B2 (en) 2019-12-05 2023-11-21 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
WO2021127283A2 (fr) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Agents de dégradation d'irak et leurs utilisations
IL293917A (en) 2019-12-17 2022-08-01 Kymera Therapeutics Inc Iraq joints and their uses
CN115297931A (zh) 2019-12-23 2022-11-04 凯麦拉医疗公司 Smarca降解剂和其用途
WO2021159021A1 (fr) 2020-02-05 2021-08-12 Puretech Lyt, Inc. Promédicaments lipidiques de neurostéroïdes
CA3170411A1 (fr) 2020-03-03 2021-09-10 Christopher L. Vandeusen Inhibiteurs d'eif4e et leurs utilisations
CA3171258A1 (fr) 2020-03-19 2021-09-23 Nan JI Agents de degradation de mdm2 et leurs utilisations
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
TW202220653A (zh) 2020-07-30 2022-06-01 美商凱麥拉醫療公司 治療突變淋巴瘤之方法
AU2021327130A1 (en) 2020-08-17 2023-03-02 Bicycletx Limited Bicycle conjugates specific for Nectin-4 and uses thereof
WO2022120353A1 (fr) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
KR20230131189A (ko) 2020-12-02 2023-09-12 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
EP4008324A1 (fr) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinaisons comprenant un inhibiteur d'une protéine anti-apoptotique, telle que bcl-2, bcl-xl, bclw ou mcl-1, et un inhibiteur de voie de signalisation notch pour le traitement du cancer
EP4255409A1 (fr) 2020-12-07 2023-10-11 Cellestia Biotech AG Combinaisons pharmaceutiques pour le traitement du cancer
WO2022167457A1 (fr) 2021-02-02 2022-08-11 Liminal Biosciences Limited Antagonistes de gpr84 et leurs utilisations
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Ｇｐｒ８４アンタゴニストおよびその使用
IL304905A (en) 2021-02-15 2023-10-01 Kymera Therapeutics Inc IRAK4 joints and their uses
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
EP4323066A1 (fr) 2021-04-16 2024-02-21 Ikena Oncology, Inc. Inhibiteurs de mek et leurs utilisations
EP4392421A1 (fr) 2021-08-25 2024-07-03 PIC Therapeutics, Inc. Inhibiteurs d'eif4e et leurs utilisations
CN118103368A (zh) 2021-08-25 2024-05-28 皮克医疗公司 Eif4e抑制剂及其用途
AU2022405016A1 (en) 2021-12-09 2024-06-06 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders for treatment of cancers
WO2023114984A1 (fr) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
WO2023173057A1 (fr) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Inhibiteurs de mek et leurs utilisations
WO2023173053A1 (fr) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Inhibiteurs de mek et leurs utilisations
WO2023211889A1 (fr) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Composés polymorphes et leurs utilisations
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof
WO2024028364A1 (fr) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyle et antagonistes de gpr84 apparentés et leurs utilisations
WO2024028363A1 (fr) 2022-08-02 2024-02-08 Liminal Biosciences Limited Hétéroaryl-carboxamide et antagonistes de gpr84 associés et leurs utilisations
WO2024028365A1 (fr) 2022-08-02 2024-02-08 Liminal Biosciences Limited Antagonistes de gpr84 contenant de la pyridone substituée et leurs utilisations
WO2024112894A1 (fr) 2022-11-22 2024-05-30 PIC Therapeutics, Inc. Inhibiteurs d'eif4e et leurs utilisations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6134403A (ja) 1984-07-26 1986-02-18 Nec Corp 光干渉計
US5326692B1 (en) * 1992-05-13 1996-04-30 Molecular Probes Inc Fluorescent microparticles with controllable enhanced stokes shift
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5248782A (en) * 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5338854A (en) * 1991-02-13 1994-08-16 Molecular Probes, Inc. Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes
JPH0586374A (ja) 1991-09-26 1993-04-06 Teikoku Sekiyu Kk 炭水化物を可燃性のガスに分解する方法
GB9326284D0 (en) * 1993-12-23 1994-02-23 Erba Carlo Spa Pyrrolydenemethyl-derivatives and process for their preparation
JP3357462B2 (ja) 1994-06-21 2002-12-16 協和油化株式会社 立体障害性ニトロキシル化合物の製造方法
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
EP0756200B1 (fr) 1995-07-26 1999-11-10 Konica Corporation Produit photographique couleur à l'halogénure d'argent sensible à la lumière
US6342477B1 (en) * 1996-02-01 2002-01-29 Chugai Seiyaku Kabushiki Kaisha Remedies for thrombocytopenia
JP3949196B2 (ja) 1996-10-23 2007-07-25 赤穂化成株式会社 免疫抑制剤
JP3949198B2 (ja) 1996-10-23 2007-07-25 赤穂化成株式会社 Ｖ−ＡＴＰａｓｅ 脱共役 Ｈ＋ ポンプ阻害剤
GB9705035D0 (en) * 1997-03-11 1997-04-30 Pharmacia & Upjohn Spa Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation
US6162520A (en) 1997-09-17 2000-12-19 Mitsui Chemicals, Inc. Optical recording medium and dipyrromethene metal chelate compound for use therein
GB9726130D0 (en) * 1997-12-10 1998-02-11 Pharmacia & Upjohn Spa 2,2'-BI-1H-pyrrole derivatives useful in the treatment of leukemia brought on by HTLV-I
CA2315370A1 (fr) 1997-12-17 1999-06-24 Merck & Co., Inc. Antagonistes du recepteur de l'integrine
EP1813624B1 (fr) 1998-10-23 2010-08-11 Amgen Inc. Procédés et compositions pour la prévention et le traitement de l'anémie
WO2000034255A1 (fr) 1998-12-04 2000-06-15 Ontogen Corporation Thiazoles substitues mettant en oeuvre des modulateurs des selectines p, l et e pour le traitement de maladies humaines
JP2000275435A (ja) 1999-03-25 2000-10-06 Sumitomo Chem Co Ltd 光学異方体フィルムおよび液晶表示装置
JP4085574B2 (ja) 2000-01-06 2008-05-14 東レ株式会社 発光素子
US6407244B1 (en) * 2000-01-26 2002-06-18 Gemin X Biotechnologies Inc. Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases
JP2001223081A (ja) 2000-02-08 2001-08-17 Toray Ind Inc 発光素子
JP2001223082A (ja) 2000-02-08 2001-08-17 Toray Ind Inc 発光素子
JP4058881B2 (ja) 2000-04-12 2008-03-12 東レ株式会社 発光素子
JP2001307884A (ja) 2000-04-26 2001-11-02 Toray Ind Inc 発光素子
JP2001330729A (ja) 2000-05-23 2001-11-30 Sumitomo Chem Co Ltd 光学異方体フィルムおよび液晶表示装置
JP2001330730A (ja) 2000-05-23 2001-11-30 Sumitomo Chem Co Ltd 光学異方体フィルムおよび液晶表示装置
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
ES2304135T3 (es) * 2001-07-18 2008-09-16 Gemin X Biotechnologies Inc. Compuestos tipo pirrol, composiciones y metodos para tratar el cancer, tratar enfermedades virales y causar inmunosupresion.
RU2352568C9 (ru) 2002-08-09 2009-06-27 Астразенека Аб [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5
EP1644363B1 (fr) 2003-05-30 2012-02-22 Gemin X Pharmaceuticals Canada Inc. Composes triheterocycliques, compositions et procedes de traitement du cancer
US20060035945A1 (en) * 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
WO2005117908A2 (fr) * 2004-05-28 2005-12-15 Gemin X Biotechnologies, Inc. Composes triheterocycliques, compositions et methodes pour le traitement du cancer ou de maladies virales
WO2006089397A1 (fr) 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Procédés pour traiter l’arthrite à l’aide de composés trihétérocycliques
US20080051400A1 (en) 2006-07-06 2008-02-28 Gemin X Biotechnologies Inc. Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound

Also Published As

Publication number Publication date
JP4980715B2 (ja) 2012-07-18
HRP20120379T1 (hr) 2012-05-31
NO20056057L (no) 2006-02-28
US20080318903A1 (en) 2008-12-25
WO2004106328A1 (fr) 2004-12-09
SI1644363T1 (sl) 2012-07-31
EP1644363B1 (fr) 2012-02-22
PL1644363T3 (pl) 2012-07-31
EP1644363A1 (fr) 2006-04-12
US20080318902A1 (en) 2008-12-25
MXPA05012799A (es) 2006-02-22
BRPI0410870A (pt) 2006-07-04
AU2004242928A1 (en) 2004-12-09
PT1644363E (pt) 2012-05-18
CN1832939B (zh) 2010-04-28
RU2360913C2 (ru) 2009-07-10
RU2005141553A (ru) 2006-07-27
US20120004224A1 (en) 2012-01-05
CY1113038T1 (el) 2016-04-13
ZA200509718B (en) 2007-03-28
US8420638B2 (en) 2013-04-16
US20050014802A1 (en) 2005-01-20
IL172189A (en) 2014-01-30
ATE546456T1 (de) 2012-03-15
CA2527583A1 (fr) 2004-12-09
JP2007502845A (ja) 2007-02-15
IL172189A0 (en) 2011-08-01
CN1832939A (zh) 2006-09-13
KR101168441B1 (ko) 2012-07-25
ES2382377T3 (es) 2012-06-07
NO333006B1 (no) 2013-02-18
KR20060036054A (ko) 2006-04-27
DK1644363T3 (da) 2012-05-29
CA2527583C (fr) 2013-12-17
NZ543897A (en) 2009-04-30
US7425553B2 (en) 2008-09-16
AU2004242928B2 (en) 2011-03-10
US7709477B2 (en) 2010-05-04

Similar Documents

Publication Publication Date Title
HK1082737A1 (en) Triheterocyclic compounds, compositions, and methods for treating cancer
WO2005117908A3 (fr) Composes triheterocycliques, compositions et methodes pour le traitement du cancer ou de maladies virales
GEP20063938B (en) Hepatitis c virus inhibitors
EA200801025A1 (ru) Композиция и синтез новых реагентов для ингибирования репликации вич
MXPA02007271A (es) Compuestos de tipo pirrol, composiciones que los contienen, y metodos para el tratamiento de cancer o enfermedades virales.
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
EA200900156A1 (ru) Пиридазиновое соединение (варианты), способ его получения (варианты), способ лечения или профилактики инфекционного вирусного гепатита с с его помощью, композиция и лекарственное средство на его основе
WO2007084413A3 (fr) Procedes de traitement de l’hepatite c
MY148690A (en) Novel macrocyclic inhibitors of hepatitis c virus replication
BRPI0407699A (pt) Inibidores de rna-polimerase dependente de rna de vìrus de hepatite c e composições e tratamentos que os utilizam
WO2003026587A3 (fr) Composes pour traiter le virus de l'hepatite c
HK1085675A1 (en) Anticancer compounds
TW200510317A (en) Caspase inhibitors and uses thereof
ATE238981T1 (de) Antitumorwirkstoffe
MXPA04006041A (es) Antivirales de piridoquinoxalina.
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
WO2003053332A3 (fr) Composition et procede pour le traitement d'une infection virale
WO2007059356A3 (fr) Inhibiteurs de l'ubiquitine e1
MXPA03005374A (es) Carbazoles antitumorales.
ATE479680T1 (de) Imidazolidinonylaminopyrimidinverbindungen zur behandlung von krebs
MXPA04000402A (es) Compuestos de tipo pirrol, composiciones que los contienen, y metodos que los emplean para el tratamiento de cancer y enfermedades virales y para causar inmunosupresion.
ATE493408T1 (de) Antiinfektiöse mittel
WO2003015714A3 (fr) Compositions et methodes therapeutiques pour infections virales
TW200505872A (en) Hepatitis C virus inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170528